Novo Nordisk layoffs have started in Denmark, where the drugmaker plans to cut 5,000 jobs as part of 9,000 global redundancies announced in early September 2025. The process began this week, according to Danish unions, amid a wider restructuring under CEO Maziar Mike Doustdar and a parallel return‑to‑office mandate for office staff.
Layoffs start: unions confirm notifications to staff
Danish unions including Djøf, HK Privat, Pharmadanmark and Lederne report that members at Novo Nordisk have begun receiving termination notices. Djøf says it is assisting affected employees with legal and career advice as the company proceeds department by department. The 5,000 Danish redundancies are part of the 9,000 job cuts worldwide previously communicated by the firm.
Restructuring plan: cost savings and a tighter operating model
The company’s reorganisation aims to streamline corporate functions and speed up decision‑making after years of rapid expansion. Management has indicated targeted cost savings of around DKK 8 billion (€1.07 billion), with reductions expected to focus on administrative and support functions while core manufacturing and sales operations continue.
Return‑to‑office: five days a week from January
Alongside the cuts, Novo Nordisk has instructed office‑based employees to return to the office five days a week from 1 January 2026, replacing the previous patchwork of hybrid arrangements.
The company says the policy is intended to strengthen collaboration and accelerate decisions during the transformation. Some unions have criticised the move, arguing that flexibility and performance can coexist.
Investor reaction: shares recover despite job cuts
Despite the scale of the layoffs, Novo Nordisk’s share price recovered in the sessions following the announcement, reflecting investor expectations for improved efficiency and profitability as the company refocuses on its core obesity and diabetes portfolios.
Union sign‑ups surge after announcement
Since the September announcement, Danish trade unions have reported a marked increase in new members, including from Novo Nordisk sites in Bagsværd, Hillerød, Måløv and Copenhagen. The uptick is attributed to heightened job‑security concerns and the complexity of Danish labour rules in large‑scale redundancies.
Why it matters for Denmark and the Nordics
Novo Nordisk is one of Denmark’s flagship companies and a major private employer. A 5,000‑position reduction concentrated in Denmark is significant for local labour markets, though national authorities maintain confidence in the wider economy.
For Nordic readers, the case illustrates how global competition in anti‑obesity medicines is reshaping corporate strategies—and how union membership can become a tool for workers navigating rapid restructuring.
The first layoff notices in Denmark mark the operational start of Novo Nordisk’s restructuring. Watch for the final distribution of cuts across functions, the impact of the return‑to‑office policy on retention and productivity, and whether the surge in unionisation endures beyond the current cycle.
